Also known as Actoplus Met 15/850, Actoplus Met 15/500, Actoplus Met 15/1000, Actoplus Met 30/1000, Duetact 30/4, Duetact 30/2, and Actos
Pioglitazone is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action to treat diabetes. It is used to improve glucose control in adults over the age of 18 with type 2 diabetes. Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe, Glizone and Pioz in India by Zydus Cadila and USV Limited, respectively and Zactos in Mexico by Takeda Pharmaceuticals. Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion. Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events. However, pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries.Source: Wikipedia
Estimated Total Cost: $184.24 for an average of 28 days supply
Patients are most commonly prescribed pioglitazone to treat diabetes, diabetic kidney disease, folate deficiency, and benign kidney cyst.